Identification of Modulators That Activate the Constitutive Androstane Receptor From the Tox21 10K Compound Library.


Journal

Toxicological sciences : an official journal of the Society of Toxicology
ISSN: 1096-0929
Titre abrégé: Toxicol Sci
Pays: United States
ID NLM: 9805461

Informations de publication

Date de publication:
01 01 2019
Historique:
pubmed: 25 9 2018
medline: 20 12 2019
entrez: 25 9 2018
Statut: ppublish

Résumé

The constitutive androstane receptor (CAR; NR1I3) is a nuclear receptor involved in all phases of drug metabolism and disposition. However, recently it's been implicated in energy metabolism, tumor progression, and cancer therapy as well. It is, therefore, important to identify compounds that induce human CAR (hCAR) activation to predict drug-drug interactions and potential therapeutic usage. In this study, we screen the Tox21 10,000 compound collection to characterize hCAR activators. A potential novel structural cluster of compounds was identified, which included nitazoxanide and tenonitrozole, whereas known structural clusters, such as flavones and prazoles, were also detected. Four compounds, neticonazole, diphenamid, phenothrin, and rimcazole, have been identified as novel hCAR activators, one of which, rimcazole, shows potential selectivity toward hCAR over its sister receptor, the pregnane X receptor (PXR). All 4 compounds translocated hCAR from the cytoplasm into the nucleus demonstrating the first step to CAR activation. Profiling these compounds as hCAR activators would enable an estimation of drug-drug interactions, as well as identify prospective therapeutically beneficial drugs.

Identifiants

pubmed: 30247703
pii: 5106019
doi: 10.1093/toxsci/kfy242
pmc: PMC6657574
doi:

Substances chimiques

Constitutive Androstane Receptor 0
NR1I3 protein, human 0
Receptors, Cytoplasmic and Nuclear 0
Small Molecule Libraries 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

282-292

Subventions

Organisme : NIGMS NIH HHS
ID : R01 GM121550
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM107058
Pays : United States

Références

J Biomol Screen. 1999;4(2):67-73
pubmed: 10838414
Res Commun Chem Pathol Pharmacol. 1984 May;44(2):215-26
pubmed: 6377421
Curr Drug Metab. 2003 Dec;4(6):515-25
pubmed: 14683479
Int J Dermatol. 1996 May;35(5):371-3
pubmed: 8734665
Microbiol Immunol. 2002;46(7):433-9
pubmed: 12222929
Clin Gastroenterol Hepatol. 2006 Mar;4(3):320-4
pubmed: 16527695
Neuro Oncol. 2013 Nov;15(11):1469-78
pubmed: 24101737
J Agric Food Chem. 2010 Feb 24;58(4):2168-73
pubmed: 20099825
J Biol Chem. 2003 May 9;278(19):17277-83
pubmed: 12611900
Curr Drug Metab. 2005 Aug;6(4):329-39
pubmed: 16101572
Eur J Pharmacol. 1991 Aug 29;201(2-3):251-2
pubmed: 1686761
Mol Cell Biol. 1999 Sep;19(9):6318-22
pubmed: 10454578
Sci Rep. 2014 Sep 26;4:6437
pubmed: 25257666
Methods Mol Biol. 2016;1473:111-22
pubmed: 27518629
Eur J Pharm Sci. 2001 Jul;13(4):343-68
pubmed: 11408150
Lancet. 2006 Jul 8;368(9530):124-9
pubmed: 16829296
Annu Rev Pharmacol Toxicol. 2008;48:1-32
pubmed: 17608617
J Pharmacol Exp Ther. 2011 Nov;339(2):662-77
pubmed: 21859929
Mol Endocrinol. 2015 Nov;29(11):1558-70
pubmed: 26407237
Curr Med Chem. 2009;16(27):3480-675
pubmed: 19515014
J Biol Chem. 2001 Oct 12;276(41):37739-42
pubmed: 11459851
Front Microbiol. 2018 May 16;9:1003
pubmed: 29867894
Sci Rep. 2015 May 20;5:10405
pubmed: 25993555
J Pharm Pharmacol. 1982 Jun;34(6):388-90
pubmed: 6124624
Br J Pharmacol. 2013 Apr;168(8):1923-32
pubmed: 23231652
Toxicology. 2012 Mar 29;294(1):17-26
pubmed: 22310298
Sci Transl Med. 2011 Apr 27;3(80):80ps16
pubmed: 21525397
Cancer Res. 2004 Oct 15;64(20):7197-200
pubmed: 15492232
Trans R Soc Trop Med Hyg. 2012 Mar;106(3):167-73
pubmed: 22301075
Drug Metab Dispos. 2010 Dec;38(12):2091-5
pubmed: 20736325
J Biol Chem. 2003 Apr 18;278(16):14146-52
pubmed: 12571232
Toxicology. 2017 Jun 15;385:48-58
pubmed: 28478275
Life Sci. 1986 Jun 23;38(25):2329-37
pubmed: 2873494
Mol Aspects Med. 2009 Oct;30(5):297-343
pubmed: 19427329
Antiviral Res. 2008 Jan;77(1):56-63
pubmed: 17888524
Mol Pharmacol. 2018 Mar;93(3):239-250
pubmed: 29351922
Methods Mol Biol. 2016;1473:123-34
pubmed: 27518630
J Pharmacol Exp Ther. 2018 May;365(2):262-271
pubmed: 29440451
J Pharmacol Exp Ther. 2006 Jun;317(3):1200-9
pubmed: 16513849
Endocrinology. 2018 Feb 1;159(2):744-753
pubmed: 29216352
J Biol Chem. 2008 Nov 7;283(45):30650-7
pubmed: 18784074
Biochem Pharmacol. 2018 Feb;148:253-264
pubmed: 29309761
Protein Cell. 2014 Feb;5(2):113-23
pubmed: 24474196
Mol Pharmacol. 2008 Aug;74(2):443-53
pubmed: 18492798
Wiad Parazytol. 1969;15(3):433-5
pubmed: 5349988
Science. 1967 Jan 13;155(3759):210-7
pubmed: 17738227
Sci Rep. 2014 Jul 11;4:5664
pubmed: 25012808
J Pharmacol Exp Ther. 2002 Mar;300(3):1070-4
pubmed: 11861817
Drug Metab Dispos. 2009 May;37(5):1098-106
pubmed: 19196842
Neural Netw. 2006 Jul-Aug;19(6-7):723-33
pubmed: 16774731
Mol Cancer Ther. 2016 Mar;15(3):392-401
pubmed: 26823489

Auteurs

Caitlin Lynch (C)

Division of Pre-Clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland 20892.

Bryan Mackowiak (B)

Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, Maryland 21201.

Ruili Huang (R)

Division of Pre-Clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland 20892.

Linhao Li (L)

Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, Maryland 21201.

Scott Heyward (S)

BioIVT, Baltimore, Maryland 21227.

Srilatha Sakamuru (S)

Division of Pre-Clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland 20892.

Hongbing Wang (H)

Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, Maryland 21201.

Menghang Xia (M)

Division of Pre-Clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland 20892.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH